Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment options for recurrent lymphomas.

R I Fisher1, P J Stiff

  • 1Section of Hematology/Oncology, Loyola University Stritch School of Medicine, Maywood.

Seminars in Oncology
|April 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.

Bone marrow transplantation·2013
Same author

A potential role for B cells in suppressed immune responses in cord blood transplant recipients.

Bone marrow transplantation·2012
Same author

Comparison of early quality of life outcomes in autologous and allogeneic transplant patients.

Bone marrow transplantation·2012

Bone marrow transplantation offers a curative option for aggressive non-Hodgkin

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Prognosis for aggressive non-Hodgkin's lymphomas (NHL) patients with refractory disease has improved.
  • Bone marrow transplantation (BMT) is now a primary curative treatment for relapsed or refractory NHL.
  • Conventional chemotherapy alone has limited efficacy for salvaging these patients.

Purpose of the Study:

  • To review the current role of bone marrow transplantation in treating aggressive non-Hodgkin's lymphomas.
  • To discuss the importance of pre-transplantation chemotherapy.
  • To highlight ongoing research in preparative regimens and alternative options for non-transplant candidates.

Main Methods:

  • Review of recent clinical studies and treatment guidelines for aggressive non-Hodgkin's lymphomas.

Related Experiment Videos

  • Analysis of the efficacy of bone marrow transplantation versus conventional chemotherapy.
  • Evaluation of strategies for preparative chemotherapy and radiation therapy.

    • Main Results:

    • Bone marrow transplantation significantly improves outcomes for patients with aggressive NHL who do not respond to initial chemotherapy.
    • Chemotherapy is crucial for inducing remission before transplantation.
    • Research is focused on optimizing pre-transplant conditioning regimens.
    • Investigational protocols are essential for patients ineligible for transplantation.

    Conclusions:

    • Bone marrow transplantation is the treatment of choice for aggressive non-Hodgkin's lymphomas unresponsive to initial therapy.
    • Pre-transplantation chemotherapy is vital for maximizing transplant success.
    • Further research into preparative regimens and alternative therapies is ongoing for non-transplant candidates.